SALEM, Mass. — Commonwealth Diagnostics International, Inc. (CDI), The Leader in Hydrogen and Methane Breath Testing®, is now in-network with Blue Cross and Blue Shield of Illinois (BCBSIL), the state’s largest health insurance company. This significant development is part of CDI’s ongoing efforts to enhance accessibility to its clinically validated non-invasive at-home breath tests for adults and pediatric gastrointestinal (GI) patients.
With more than 8.5 million members and 2,200 network facilities, BCBSIL’s expansive coverage plays a pivotal role in the healthcare of countless Illinois residents. CDI’s inclusion as an in-network provider stands to dramatically increase the accessibility of its breath tests, which are pivotal in diagnosing conditions such as Small Intestinal Bacterial Overgrowth (SIBO) and Intestinal Methanogen Overgrowth (IMO), along with fructose, sucrose, and lactose carbohydrate malabsorption disorders.
“Achieving in-network status with Blue Cross and Blue Shield of Illinois is a monumental step forward in our mission to continue making high-quality, patient-centric diagnostic care accessible to a wider range of participants,” said Craig Strasnick, President and CEO of CDI. “BCBSIL’s extensive network, one of the largest under the Blue Cross Blue Shield Association, ensures that our cutting-edge breath tests can reach more patients and providers, ultimately facilitating better health outcomes.”
In addition to BCBSIL, CDI maintains in-network relationships with a growing list of commercial insurance providers, including Blue Cross Blue Shield of Massachusetts, Multiplan, Health Partners of Minnesota, Veterans Affairs’ Community Care Network (CCN), Medical Cost Containment Professionals (MCCP), Three Rivers Provider Network (TRPN), CoreSource – Ohio State University Health Plan, and UCLA Medical Group (HMO only). CDI also accepts all Medicare, Medicare Advantage, and Tricare government-managed health insurance plans, ensuring that Medicare fully covers CDI tests with no balance billing to patients.
Strasnick continued, “Our market access team continues to diligently work through credentialing and contracting processes to expand our in-network coverage and help lessen the burden of diagnostic testing for patients suffering from GI conditions.”
For more information on CDI and its functional GI breath tests, visit commdx.com.
About Commonwealth Diagnostics International, Inc. (CDI):
Commonwealth Diagnostics International, Inc. (CDI) is an innovative GI health company providing industry-leading diagnostic tests and tools to help physicians identify and diagnose familiar sources of digestive distress and functional GI ailments for adults and pediatric patients. Focused on their patient-centric principles, their cost-effective portfolio of diagnostic products results in expedited treatment, better patient outcomes, and robust cost savings for the healthcare delivery system. Their expansive portfolio includes non-invasive at-home breath testing kits for Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Methane Overgrowth (IMO), and carbohydrate malabsorption disorders, as well as technology solutions, including MyGI Gateway, a cutting-edge provider portal for enhanced patient care, and MyGI Health, a cloud-based platform that enables patients to monitor, manage and understand their GI-related symptoms. Operating out of its CLIA-certified laboratory and as an FDA-registered ISO 13485-certified medical device manufacturer, CDI prides itself on partnerships with industry-leading health systems, hospitals, and private practices worldwide. For more information, visit commdx.com.
